a Department of Otolaryngology-Head and Neck Surgery, The University of California, Davis , Sacramento , CA , USA.
b Department of Otolaryngology-Head and Neck Surgery, Indiana University , Indianapolis , IN , USA.
Hum Vaccin Immunother. 2019;15(7-8):1920-1928. doi: 10.1080/21645515.2019.1600985. Epub 2019 May 7.
The incidence of oropharyngeal cancer (OPC) related to infection with human papillomavirus (HPV) is rising, making it now the most common HPV-related malignancy in the United States. These tumors present differently than traditional mucosal head and neck cancers, and those affected often lack classic risk factors such as tobacco and alcohol use. Currently, there are no approved approaches for prevention and early detection of disease, thus leading many patients to present with advanced cancers requiring intense surgical or nonsurgical therapies resulting in significant side effects and cost to the health-care system. In this review, we outline the evolving epidemiology of HPV-related OPC. We also summarize the available evidence corresponding to HPV-related OPC prevention, including efficacy and safety of the HPV vaccine in preventing oral HPV infections. Finally, we describe emerging techniques for identifying and screening those who may be at high risk for developing these tumors.
人乳头瘤病毒(HPV)感染相关的口咽癌(OPC)发病率正在上升,使其成为美国目前最常见的 HPV 相关恶性肿瘤。这些肿瘤的表现与传统的黏膜头颈部癌症不同,受影响的患者通常缺乏烟草和酒精使用等典型的危险因素。目前,尚无针对疾病预防和早期检测的批准方法,因此导致许多患者出现晚期癌症,需要进行强化的手术或非手术治疗,从而给医疗保健系统带来严重的副作用和成本。在这篇综述中,我们概述了 HPV 相关 OPC 的不断变化的流行病学。我们还总结了 HPV 相关 OPC 预防的现有证据,包括 HPV 疫苗在预防口腔 HPV 感染方面的疗效和安全性。最后,我们描述了用于识别和筛选那些可能患有这些肿瘤的高风险人群的新兴技术。